company background image
OTSU logo

Otsuka Pakistan KASE:OTSU Stock Report

Last Price

PK₨117.32

Market Cap

PK₨1.4b

7D

-0.2%

1Y

62.0%

Updated

21 Jun, 2024

Data

Company Financials

Otsuka Pakistan Limited

KASE:OTSU Stock Report

Market Cap: PK₨1.4b

OTSU Stock Overview

Manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan.

OTSU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Otsuka Pakistan Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Otsuka Pakistan
Historical stock prices
Current Share PricePK₨117.32
52 Week HighPK₨185.89
52 Week LowPK₨73.00
Beta0.36
11 Month Change-6.38%
3 Month Change-9.75%
1 Year Change62.04%
33 Year Change-57.01%
5 Year Change-39.25%
Change since IPO601.02%

Recent News & Updates

Recent updates

Shareholder Returns

OTSUPK PharmaceuticalsPK Market
7D-0.2%-0.7%2.0%
1Y62.0%87.9%65.5%

Return vs Industry: OTSU underperformed the PK Pharmaceuticals industry which returned 91.3% over the past year.

Return vs Market: OTSU underperformed the PK Market which returned 64.4% over the past year.

Price Volatility

Is OTSU's price volatile compared to industry and market?
OTSU volatility
OTSU Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.3%
10% most volatile stocks in PK Market8.2%
10% least volatile stocks in PK Market3.2%

Stable Share Price: OTSU has not had significant price volatility in the past 3 months.

Volatility Over Time: OTSU's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988362Moin-ur Rehmanwww.otsuka.pk

Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company’s products include electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products, such as aminoleban oral, proten gold, pan-amin G, aminoleban injection, and aminovel 600; and therapeutic drugs, which include mucosta tablets and pletaal, as well as oral rehydration therapy. It also engages in the trading of pharmaceutical products, nutritional foods, and medical equipment.

Otsuka Pakistan Limited Fundamentals Summary

How do Otsuka Pakistan's earnings and revenue compare to its market cap?
OTSU fundamental statistics
Market capPK₨1.42b
Earnings (TTM)PK₨84.34m
Revenue (TTM)PK₨2.83b

16.8x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OTSU income statement (TTM)
RevenuePK₨2.83b
Cost of RevenuePK₨2.28b
Gross ProfitPK₨550.39m
Other ExpensesPK₨466.05m
EarningsPK₨84.34m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)6.97
Gross Margin19.47%
Net Profit Margin2.98%
Debt/Equity Ratio136.4%

How did OTSU perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

22%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.